ZONTIVITY Drug Patent Profile
✉ Email this page to a colleague
When do Zontivity patents expire, and what generic alternatives are available?
Zontivity is a drug marketed by Xspire Pharma and is included in one NDA. There are two patents protecting this drug.
This drug has one hundred and sixty-four patent family members in thirty-seven countries.
The generic ingredient in ZONTIVITY is vorapaxar sulfate. Additional details are available on the vorapaxar sulfate profile page.
DrugPatentWatch® Generic Entry Outlook for Zontivity
Zontivity was eligible for patent challenges on May 8, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 23, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ZONTIVITY
International Patents: | 164 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 47 |
Clinical Trials: | 5 |
Patent Applications: | 7 |
Drug Prices: | Drug price information for ZONTIVITY |
What excipients (inactive ingredients) are in ZONTIVITY? | ZONTIVITY excipients list |
DailyMed Link: | ZONTIVITY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZONTIVITY
Generic Entry Date for ZONTIVITY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ZONTIVITY
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Vanderbilt University | Phase 4 |
Vanderbilt University Medical Center | Phase 4 |
University of Florida | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for ZONTIVITY
US Patents and Regulatory Information for ZONTIVITY
ZONTIVITY is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZONTIVITY is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ZONTIVITY
Thrombin receptor antagonists
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
Thrombin receptor antagonists
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xspire Pharma | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Xspire Pharma | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZONTIVITY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Xspire Pharma | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZONTIVITY
See the table below for patents covering ZONTIVITY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 60129698 | ⤷ Try a Trial | |
Canada | 2410177 | ANTAGONISTES DU RECEPTEUR DE LA THROMBINE (THROMBIN RECEPTOR ANTAGONISTS) | ⤷ Try a Trial |
European Patent Office | 1982984 | Antagonistes de récepteur de thrombine tricyclique et compositions pharmaceutiques les contenant (Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them) | ⤷ Try a Trial |
Germany | 60317493 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZONTIVITY
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1495018 | C 2015 030 | Romania | ⤷ Try a Trial | PRODUCT NAME: VORAPAXAR SAU O SARE ACCEPTABILA FARMACEUTIC SAU SOLVATAL ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/14/976/001, EU/1/14/976/002, EU/1/14/976/003, EU/1/14/976/004, EU/1/14/976/005, EU/1/14/976/006; DATE OF NATIONAL AUTHORISATION: 20150119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/976/001, EU/1/14/976/002, EU/1/14/976/003, EU/1/14/976/004, EU/1/14/976/005, EU/1/14/976/006; DATE OF FIRST AUTHORISATION IN EEA: 20150119 |
1495018 | 300746 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: VORAPAXAR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER VORAPAXARSULFAAT; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150121 |
1495018 | S1500036 | Hungary | ⤷ Try a Trial | PRODUCT NAME: VORAPAXAR; REGISTRATION NO/DATE: EU/1/14/976 20150119 |
1495018 | 2015C/037 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VORAPAXAR, OU SON SEL OU SOLVAT PHARMACOLOGIQUEMENT ADMISSIBLE; AUTHORISATION NUMBER AND DATE: EU/1/14/976/001 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |